Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Stock Rating Raised to “Hold” at Wall Street Zen

Wall Street Zen upgraded shares of Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) from a sell rating to a hold rating in a research report sent to investors on Sunday,Wall Street Zen reports.

Other equities analysts also recently issued reports about the stock. Wedbush reiterated an “outperform” rating and issued a $40.00 target price on shares of Damora Therapeutics, Inc. Common Stock in a report on Tuesday, September 29th. Guggenheim increased their price target on shares of Damora Therapeutics, Inc. Common Stock from $40.00 to $60.00 and gave the company a “buy” rating in a research report on Friday, September 25th. Weiss Ratings restated a “sell (d-)” rating on shares of Damora Therapeutics, Inc. Common Stock in a report on Monday, September 14th. Jefferies Financial Group started coverage on shares of Damora Therapeutics, Inc. Common Stock in a research report on Monday, July 27th. They issued a “buy” rating and a $50.00 price objective on the stock. Finally, TD Cowen upgraded shares of Damora Therapeutics, Inc. Common Stock to a “strong-buy” rating in a research note on Monday, August 24th. Three research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Damora Therapeutics, Inc. Common Stock currently has an average rating of “Buy” and a consensus target price of $46.50.

Damora Therapeutics, Inc. Common Stock Stock Performance

Shares of NASDAQ DMRA opened at $21.08 on Friday. Damora Therapeutics, Inc. Common Stock has a 12-month low of $4.95 and a 12-month high of $38.33. The stock’s fifty day simple moving average is $26.55 and its two-hundred day simple moving average is $25.94. The stock has a market capitalization of $1.30 billion, a PE ratio of -6.26 and a beta of 1.43.

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) last released its quarterly earnings results on Monday, August 10th. The company reported ($0.39) EPS for the quarter, topping the consensus estimate of ($0.45) by $0.06. On average, equities analysts predict that Damora Therapeutics, Inc. Common Stock will post -2.06 earnings per share for the current fiscal year.

Insider Activity

In other news, CEO Jennifer Jarrett bought 12,500 shares of Damora Therapeutics, Inc. Common Stock stock in a transaction that occurred on Friday, September 25th. The stock was bought at an average price of $20.23 per share, for a total transaction of $252,875.00. Following the purchase, the chief executive officer directly owned 512,500 shares of the company’s stock, valued at approximately $10,367,875. The trade was a 2.50% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 0.40% of the stock is currently owned by insiders.

Institutional Trading of Damora Therapeutics, Inc. Common Stock

Several large investors have recently added to or reduced their stakes in the company. Arizona State Retirement System acquired a new stake in shares of Damora Therapeutics, Inc. Common Stock during the second quarter worth about $260,000. Squarepoint Ops LLC purchased a new position in Damora Therapeutics, Inc. Common Stock during the 2nd quarter worth approximately $303,000. Seven Fleet Capital Management LP acquired a new stake in Damora Therapeutics, Inc. Common Stock during the 2nd quarter valued at approximately $7,398,000. Finally, Braidwell LP purchased a new stake in shares of Damora Therapeutics, Inc. Common Stock in the 2nd quarter valued at $42,146,000. Hedge funds and other institutional investors own 14.20% of the company’s stock.

About Damora Therapeutics, Inc. Common Stock

Galecto, Inc, a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis.